BioNTech (NASDAQ:BNTX) Trading 2% Higher – Still a Buy?

BioNTech SE (NASDAQ:BNTX)’s share price shot up 2% during trading on Monday . The stock traded as high as $115.98 and last traded at $115.39. 290,685 shares changed hands during trading, a decline of 64% from the average session volume of 810,922 shares. The stock had previously closed at $113.13.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft boosted their target price on BioNTech from $95.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, September 19th. HC Wainwright reissued a “buy” rating and set a $150.00 target price on shares of BioNTech in a research note on Monday, November 18th. HSBC lifted their price target on shares of BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a research note on Monday, October 7th. TD Cowen dropped their price objective on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a report on Tuesday, November 5th. Finally, Jefferies Financial Group raised shares of BioNTech from a “hold” rating to a “buy” rating and upped their target price for the stock from $96.00 to $150.00 in a research note on Tuesday, September 17th. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $138.67.

BioNTech Stock Performance

The stock has a market capitalization of $28.94 billion, a P/E ratio of -57.48 and a beta of 0.26. The stock has a 50 day simple moving average of $113.42 and a two-hundred day simple moving average of $98.19. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating the consensus estimate of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. During the same period last year, the business earned $0.73 earnings per share. The firm’s revenue was up 38.9% on a year-over-year basis. On average, equities analysts forecast that BioNTech SE will post -3.68 EPS for the current fiscal year.

Institutional Investors Weigh In On BioNTech

Institutional investors and hedge funds have recently modified their holdings of the company. GAMMA Investing LLC raised its stake in BioNTech by 86.9% in the second quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock valued at $41,000 after buying an additional 238 shares during the period. EverSource Wealth Advisors LLC raised its stake in BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after acquiring an additional 252 shares during the period. Planning Capital Management Corp raised its stake in BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after acquiring an additional 450 shares during the period. Blue Trust Inc. lifted its holdings in BioNTech by 491.1% during the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after purchasing an additional 388 shares during the last quarter. Finally, Daiwa Securities Group Inc. boosted its position in BioNTech by 430.3% during the second quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company’s stock worth $155,000 after purchasing an additional 1,562 shares during the period. 15.52% of the stock is owned by institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.